Gossamer Bio, Inc.GOSSNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
27.52%
↓ 92% below average
Average (34q)
327.78%
Historical baseline
Range
High:10500.00%
Low:-14.07%
Volatility
3207.7%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 27.52% |
| Q2 2025 | 9.29% |
| Q1 2025 | 5.34% |
| Q4 2024 | 3.48% |
| Q3 2024 | -0.54% |
| Q2 2024 | 8.32% |
| Q1 2024 | 8.08% |
| Q4 2023 | -3.94% |
| Q3 2023 | -14.07% |
| Q2 2023 | -3.93% |
| Q1 2023 | -8.95% |
| Q4 2022 | -6.74% |
| Q3 2022 | 4.53% |
| Q2 2022 | 0.61% |
| Q1 2022 | 3.40% |
| Q4 2021 | -5.23% |
| Q3 2021 | -2.55% |
| Q2 2021 | 5.96% |
| Q1 2021 | 7.50% |
| Q4 2020 | -7.02% |
| Q3 2020 | 8.17% |
| Q2 2020 | -6.59% |
| Q1 2020 | -2.77% |
| Q4 2019 | 6.10% |
| Q3 2019 | 12.54% |
| Q2 2019 | 42.80% |
| Q1 2019 | -3.44% |
| Q4 2018 | 37.20% |
| Q3 2018 | 137.79% |
| Q2 2018 | 202.21% |
| Q1 2018 | 288.74% |
| Q4 2017 | 218.40% |
| Q3 2017 | 10500.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |